Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,
#2936 Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3
Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) G3 are rare with a poor outcome. Molecular data for GEP NEN G3 is limited and the 2019 WHO classification is based on morphology and proliferation rate.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Elvebakken H
Authors: Venizelos A, Elvebakken H, Perren A, Hjortland G, Sundlöv A,
Keywords: molecular genetics, neuroendocrine carcinoma, neuroendocrine tumors, gastroenteropancreatic, mutations,
#2822 Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors
Introduction: Platinum-based chemotherapy has been the recommended treatment for metastatic high-grade pancreatic neuroendocrine neoplasms (panNEN). This strategy has been questioned for pancreatic neuroendocrine tumor grade 3 (panNET G3). The most optimal treatment strategy for low/intermediate grade panNETs that show progression to a high grade (secondary panNET G3) is unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Mollazadegan K, Botling J, Welin S, Eriksson B, Skogseid B,
Keywords: pancreas, neuroendocrine tumor, treatment,
#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jann H
Authors: Schenk J, Kayser A, Wiedenmann B, Tacke F, Roderburg C,
Keywords: NEN G3, Chemotherapy, Platinum, NEC G3, NET G3,
Introduction: The update of the WHO 2017 classification of pancreatic neuroendocrine tumors (NETs) introduces the distinction between NET & NEC G3, based on histological differentiation. However, little is known about the possibility of extending this concept to non-pancreatic NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Castaño A, Capdevila J, Benavent M,
Keywords: WHO classification, NET G3, NEC G3, non-pancreatic NET, poorly differentiated,